Pacira Biosciences' Exparel Generic Competition in 2025
As of early 2024, there are no approved generic versions of Pacira Biosciences' Exparel (bupivacaine liposome injectable emulsion) available in the United States [1]. However, the patent landscape suggests that generic competition could emerge in the coming years.
When Does Exparel's Patent Protection End?
Exparel is protected by several patents. The primary U.S. patent for the drug is expected to expire in 2034 [2]. However, other patents related to its formulation and manufacturing may have earlier expiration dates, potentially opening avenues for generic entry sooner [3]. DrugPatentWatch.com provides detailed information on the patent status of pharmaceuticals, including Exparel [3].
What Could Enable Generic Entry Before 2034?
Generic manufacturers might seek to enter the market by challenging existing patents or by developing alternative formulations or manufacturing processes that do not infringe on Pacira's intellectual property [4]. Litigation surrounding patent validity or infringement is common in the pharmaceutical industry and can significantly alter a drug's market exclusivity timeline [4].
How Does Exparel Work?
Exparel is a non-opioid local anesthetic that utilizes DepoFoam extended-release drug delivery technology [1]. This technology allows for the sustained release of bupivacaine, providing pain relief for up to 72 hours post-surgery [1]. This mechanism differentiates it from standard bupivacaine solutions, which offer shorter durations of analgesia [1].
What Are the Alternatives to Exparel?
Alternatives to Exparel for post-operative pain management include traditional opioid analgesics, other non-opioid analgesics, and other local anesthetic infiltration techniques [5]. The choice of pain management strategy often depends on the type of surgery, patient factors, and clinician preference [5].
What Factors Influence Generic Drug Pricing?
Once generic competition emerges, pricing typically becomes more competitive [6]. Factors influencing generic drug pricing include the number of generic manufacturers in the market, manufacturing costs, and regulatory hurdles [6].
What Are the Risks Associated with Generic Drug Entry?
For the brand-name manufacturer, the primary risk of generic entry is a significant decline in market share and revenue [7]. For patients and healthcare providers, risks can include ensuring the bioequivalence and efficacy of generic products, although regulatory bodies like the FDA have stringent approval processes for generics [8].
What is the Regulatory Pathway for Exparel Generics?
For a generic version of Exparel to be approved by the U.S. Food and Drug Administration (FDA), it must demonstrate bioequivalence to the reference listed drug, Exparel [8]. This means the generic must deliver the same amount of active ingredient into the bloodstream over the same time period as the brand-name drug [8].
Who Are Pacira Biosciences' Competitors?
Pacira Biosciences, as a specialty pharmaceutical company, faces competition in the pain management market from companies offering various analgesic products, including opioid manufacturers and developers of other non-opioid pain relief solutions [9]. The competitive landscape is dynamic and influenced by new product development and patent expirations [9].
---
Sources:
[1] Pacira Biosciences, Inc. (n.d.). EXPையுடன் (bupivacaine liposome injectable emulsion) prescribing information. Retrieved from https://www.exparel.com/
[2] DrugPatentWatch.com. (n.d.). Exparel patent status. Retrieved from https://drugpatentwatch.com/
[3] DrugPatentWatch.com. (n.d.). Bupivacaine liposome injectable emulsion patent information. Retrieved from https://drugpatentwatch.com/
[4] U.S. Food & Drug Administration. (n.d.). Generic Drugs: Questions & Answers. Retrieved from https://www.fda.gov/drugs/generic-drugs/generic-drugs-questions-answers
[5] National Institute on Drug Abuse. (n.d.). Principles of Drug Addiction Treatment: A Research-Based Guide. Retrieved from https://www.drugabuse.gov/publications/principles-drug-addiction-treatment-research-based-guide-third-edition
[6] Generic Pharmaceutical Association. (n.d.). The Value of Generic Medicines. Retrieved from https://www.gpgp.org/
[7] U.S. Food & Drug Administration. (n.d.). ANDA Process. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/anda-process
[8] U.S. Food & Drug Administration. (n.d.). Generic Drug Bioequivalence. Retrieved from https://www.fda.gov/drugs/abbreviated-new-drug-applications-andas/generic-drug-bioequivalence
[9] Fierce Pharma. (n.d.). Pacira Biosciences news. Retrieved from https://www.fiercepharma.com/companies/pacira-biosciences